Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 16,500 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $52.10, for a total transaction of $859,650.00. Following the sale, the chairman now owns 51,476 shares in the company, valued at approximately $2,681,899.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Ionis Pharmaceuticals, Inc. (IONS) traded up 1.32% during trading on Friday, hitting $52.77. 1,061,511 shares of the stock traded hands. The stock’s market cap is $6.54 billion. The company’s 50 day moving average price is $52.96 and its 200-day moving average price is $46.75. Ionis Pharmaceuticals, Inc. has a 52-week low of $24.58 and a 52-week high of $60.01.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, May 9th. The company reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.13. The firm had revenue of $110.30 million for the quarter, compared to analysts’ expectations of $86.03 million. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. The firm’s revenue was up 199.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.52) EPS. Equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.15) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/07/30/stanley-t-crooke-sells-16500-shares-of-ionis-pharmaceuticals-inc-ions-stock-updated-updated-updated.html.
Several analysts recently commented on IONS shares. Piper Jaffray Companies set a $51.00 price target on shares of Ionis Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 10th. Needham & Company LLC restated a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 17th. BMO Capital Markets restated a “buy” rating and set a $59.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Wednesday, July 12th. Finally, TheStreet upgraded shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Wednesday, July 5th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $45.38.
Large investors have recently modified their holdings of the stock. Hanseatic Management Services Inc. acquired a new stake in shares of Ionis Pharmaceuticals during the first quarter worth approximately $138,000. Westpac Banking Corp acquired a new stake in shares of Ionis Pharmaceuticals during the first quarter worth approximately $171,000. Capstone Asset Management Co. boosted its stake in shares of Ionis Pharmaceuticals by 10.3% in the first quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock worth $207,000 after buying an additional 480 shares during the last quarter. World Asset Management Inc boosted its stake in shares of Ionis Pharmaceuticals by 27.3% in the first quarter. World Asset Management Inc now owns 5,427 shares of the company’s stock worth $218,000 after buying an additional 1,163 shares during the last quarter. Finally, Raymond James Trust N.A. boosted its stake in shares of Ionis Pharmaceuticals by 2.9% in the first quarter. Raymond James Trust N.A. now owns 5,705 shares of the company’s stock worth $229,000 after buying an additional 159 shares during the last quarter. 88.75% of the stock is currently owned by hedge funds and other institutional investors.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.